The arachnoiditis market is expected to register a significant CAGR during the forecast period (2018–2023).
Arachnoiditis is a rare medical complication caused by damage or harm to the arachnoid layer of the spinal cord. The patient suffers from profound stinging, burning and neurological problems in this condition. Arachnoiditis is a result of unsuccessful surgery, the entrance of unwanted chemical in the spinal cord or viral and bacterial infection to the spinal cord. The growing geriatric population, an increasing number of surgeries, and technological advancement in the world is propelling the growth of the market. For instance, according to the United Nations, a population which is 60 or above 60-year-old is rapidly increasing and will reach 2.1 billion in 2050 from 936 million in 2017.
The rising cost of surgical procedures and treatments, stringent regulatory policies regarding approvals and scarcity of experts to treat arachnoiditis may hamper the growth of the market during the assessment period.
The arachnoiditis market has been segmented on the basis of type, cause, diagnosis, treatment, and end-user.
On the basis of type, the market has been classified as adhesive arachnoiditis, arachnoiditis ossificans, arachnoiditis ossificans, cerebral arachnoiditis, hereditary arachnoiditis, neoplastic arachnoiditis, and optochiasmatic arachnoiditis.
The market, by cause, has been segmented into trauma/surgery induced, chemically induced, and infection-induced. The trauma/surgery induced segment is divided into spinal surgery, lumbar puncture, spinal stenosis, and others. The chemically induced segment is further divided into myelograms and epidural steroid injection. The infection-induced segment is classified into viral and fungal meningitis, and tuberculosis.
The market on the basis of diagnosis is divided into CAT scan (computerized axial tomography), MRI (magnetic resonance imaging), and Electromyogram (EMG).
On basis of treatment, the market has been divided into Physical therapy, Pain medications, Nerve stimulation, and psychological support. Physical therapy segment is further divided into hydrotherapy, massage, and hot/cold therapy. lidocaine intravenous (IV) infusion, ketamine IV infusions, and naltrexone are part of pain medications. Nerve stimulation segment is divided into spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS).
The end user segment has been classified into hospital and clinics, pharmacies, diagnostic centers, and others.
The pain medication segment is likely to hold the first position in terms of market share and nerve stimulation will grow with the maximum growth rate.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The arachnoiditis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European arachnoiditis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The arachnoiditis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The arachnoiditis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Arachnoiditis Market Share, by Region, 2017 (%)
Source: MRFR Analysis
The Americas are likely to dominate the arachnoiditis market owing to the favorable reimbursement policies, technological advancement and increasing number of surgeries in the region. For instance, in March 2017, FDA approved the new spinal surgery procedure named lumbar artificial disc replacement by activL artificial disc for the treatment of back pain
The European market is expected to be the second-largest arachnoiditis market. The market growth in this region can be attributed to the increasing geriatric population in the region, government initiatives and funding to the healthcare sector and increasing R&D activities. Moreover, a growing number of surgeries due to changing lifestyles is contributing to the growth of the market in this region.
Asia-Pacific is expected to be the fastest-growing arachnoiditis market during the forecast period owing to the increasing population, rising investments in healthcare, rising number of tuberculosis cases and expansions by market players in the region. According to the Global Tuberculosis Report 2017 published by the World Health Organization, Number Tuberculosis cases are significantly increasing and during the period 2013 to 2016, the number of new cases of tuberculosis were increased by 37%.
The market in the Middle East & Africa is expected to hold the smallest share of the arachnoiditis market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Some of the key players in the arachnoiditis market are Baxter, B. Braun Melsungen AG, Pfizer Inc., SR Pharma, Abbott, AstraZeneca, Bristol-Myers Squibb Company, DuPont, Sandoz International GmbH, Takeda Pharmaceutical Company Limited, and Novartis AG.
Arachnoiditis Market, by Type
Arachnoiditis Market, by Cause
Arachnoiditis Market, by Diagnosis
Arachnoiditis Market, by Treatment
Arachnoiditis Market, by End User
Arachnoiditis Market, by Region